Gilead drug acquired in $5B buyout fails key blood cancer trial
BioPharma
Source: biopharmadive.com
Page 34 - Michael Yee News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Michael Yee. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Michael Yee Today - Breaking & Trending Today
Jefferies Keeps Their Buy Rating on Prothena (PRTA)
Jefferies analyst Michael Yee maintained a Buy rating on Prothena (PRTA – Research Report) yesterday and set a price target of $100.00. Th...
Source: businessinsider.com
Alzheimer's drug Leqembi sales may be slow at first: Analysts
Analysts believe the Medicare registry requirement and new guidance on Leqembi's prescription label could potentially weigh on sales in the near term.
Source: cnbc.com
Sales of Alzheimer's Drug Leqembi May Be Slow Initially But Could Pick Up in 2024
Analysts believe the Medicare registry requirement and new guidance on Leqembi’s prescription label could potentially weigh on sales in the near term.
Source: nbcconnecticut.com
Wall Street Analysts Are Bullish on Top Technology Picks
There’s a lot to be optimistic about in the Technology sector as 3 analysts just weighed in on Terran Orbital Corp (LLAP – Research Report...
Source: businessinsider.com